Search results for "Compounds"

showing 10 items of 3372 documents

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma …

2019

Abstract Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF‐A and Ang‐2, suggesting that the dual VEGF‐A and Ang‐2 blocker vanucizumab (RO5520985 or RG‐7221) may improve clinical outcomes. This phase II trial evaluated the efficacy of vanucizumab plus modified (m)FOLFOX‐6 (folinic acid (leucovorin), fluorouracil (5‐FU) and oxaliplatin) ver…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyVEGF‐AVanucizumab20BevacizumabAngiopoetin-26Organoplatinum CompoundsColorectal cancerLeucovorinPhases of clinical researchFirst‐line metastatic colorectal cancerAntibodies Monoclonal HumanizedVEGF-ADisease-Free SurvivalMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineMetàstasiCàncer colorectalInternal medicineGastrointestinal CancerAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansNeoplasm MetastasisAngiopoetin‐2business.industryHazard ratiomedicine.diseaseColorectal cancerOxaliplatinBevacizumab030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisCamptothecinFluorouracilbusinessColorectal NeoplasmsFirst-line metastatic colorectal cancermedicine.drug
researchProduct

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

2019

BackgroundEribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.MethodsPatients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the…

0301 basic medicineOncologyCancer TreatmentTriple Negative Breast NeoplasmsImmunostainingToxicologyPathology and Laboratory MedicineBiochemistryMetastasis0302 clinical medicineBreast TumorsClinical endpointMedicine and Health Sciencesmetastatic breast cancer Eribulin mesylate epithelial–mesenchymal transition.AnthracyclinesTriple-negative breast cancerStainingMultidisciplinaryPharmaceuticsQRKetonesMetastatic breast cancerNeoadjuvant TherapyTreatment OutcomeSurgical OncologyOncology030220 oncology & carcinogenesisMedicineFemaleTaxoidsResearch ArticleAdultBridged-Ring CompoundsClinical Oncologymedicine.medical_specialtyAnthracyclineScienceSurgical and Invasive Medical ProceduresNeutropeniaResearch and Analysis Methods03 medical and health sciencesCancer ChemotherapyBreast cancerbreast cancerDrug TherapyInternal medicinemedicineHumansChemotherapyFuransTaxaneToxicitybusiness.industryCancers and NeoplasmsBiology and Life Sciencesmedicine.disease030104 developmental biologySpecimen Preparation and TreatmentMED/06 - ONCOLOGIA MEDICAClinical MedicinebusinessBiomarkers
researchProduct

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.

2017

Abstract Purpose The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. Patients and methods This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously tre…

0301 basic medicineOncologyDiarrheamedicine.medical_specialtyIndazolesCyclophosphamideMaximum Tolerated DosePlatinum CompoundsCarcinoma Ovarian EpithelialDisease-Free SurvivalPazopanib03 medical and health sciences0302 clinical medicineLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasms Glandular and EpithelialAdverse effectCyclophosphamideFatigueAgedOvarian NeoplasmsSulfonamidesLeukopeniabusiness.industryObstetrics and GynecologyLeukopeniaMiddle Agedmedicine.diseaseSurgeryRegimen030104 developmental biologyPyrimidinesOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisFallopian tube cancerFemalemedicine.symptomNeoplasm GradingNeoplasm Recurrence LocalbusinessOvarian cancerNeoplasms Cystic Mucinous and Serousmedicine.drugGynecologic oncology
researchProduct

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

2016

Abstract: Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura with a poor prognosis. The most active first-line regimens are platinum compounds and pemetrexed. There is no standard second-line treatment in MPM. Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. Unfortunately none of the explored targeted treatments can currently be recommended as routine treatment in MPM. We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance. We suggest that specific genetic markers are n…

0301 basic medicineOncologyDrugMesotheliomamedicine.medical_specialtyPathologyLung NeoplasmsSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectmedicine.medical_treatmentPleural NeoplasmsResistanceAntineoplastic AgentsTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsHumansMesotheliomaMolecular Targeted Therapymedia_commonPleural mesotheliomabusiness.industryPlatinum compoundsMesothelioma MalignantHematologymedicine.diseaseClinical trial030104 developmental biologyPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationPleuraMesothelioma; Pleura; Resistance; Targeted therapyMolecular ProfileHuman medicinebusinessmedicine.drug
researchProduct

Oxidative stress and frailty : a systematic review and synthesis of the best evidence

2017

Objective Oxidative stress (OS) is associated with accelerated aging. Previous studies have suggested a possible relationship between OS and frailty but this association remains unclear. We conducted a systematic review to investigate potential interactions between OS and frailty. Methods A systematic literature search of original reports providing data on ‘OS and antioxidant’ parameters and frailty was carried out across major electronic databases from inception until May 2016. Cross-sectional/case control and longitudinal studies reporting data on the association between frailty and anti-oxidants-OS biomarkers were considered for inclusion. Results were summarized with a synthesis based o…

0301 basic medicineOncologyGerontologyGenetics and Molecular Biology (all)AgingCross-sectional studyalpha-TocopherolAntioxidantesIsoprostanesmedicine.disease_causeBiochemistryAnti-oxidantAntioxidants0302 clinical medicineLongitudinal StudiesAged 80 and overFrailtyGlutathione DisulfideObstetrics and GynecologyGlutathione8-Hydroxy-2'-DeoxyguanosineSystematic searchAnti-oxidant; Frail; Frailty; Oxidative stress; Biochemistry Genetics and Molecular Biology (all); Obstetrics and Gynecologymedicine.medical_specialtyFrail ElderlyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesFrailInternal medicinemedicineHumansFrail elderlySulfhydryl CompoundsAgedAldehydesbusiness.industryCase-control studyFrailty Frail Oxidative stress Anti-oxidantEstresse OxidativoDeoxyguanosineMean ageOxidized GlutathioneOxidative Stress030104 developmental biologyCross-Sectional Studies1-Alkyl-2-acetylglycerophosphocholine EsteraseBest evidencebusinessReactive Oxygen Species030217 neurology & neurosurgeryOxidative stressBiomarkers
researchProduct

Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.

2017

<b><i>Background/Aim:</i></b> A clinical trial demonstrated that treatment with oral multikinase regorafenib improved overall survival (OS), progression-free survival (PFS), and disease control [García-Alfonso et al.: J Clin Transl Oncol 2016;18:1072-1081; Bertocchi et al.: J Chemother 2017;29:102-105]. In this study, we aimed to evaluate its effectiveness in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy with docetaxel plus prednisone. <b><i>Materials and Methods:</i></b> 60 patients were enrolled. OS has been assessed as the primary endpoint while PFS, quality o…

0301 basic medicineOncologyMaleCancer ResearchColorectal cancerPyridinesmedicine.medical_treatmentDocetaxelKaplan-Meier Estimatechemistry.chemical_compound0302 clinical medicineQuality of lifeAntineoplastic Combined Chemotherapy ProtocolsMedicineRegorafenibAged 80 and overMetastatic colorectal cancerGeneral MedicineMiddle AgedProstatic Neoplasms Castration-ResistantTreatment OutcomeOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleTaxoidsColorectal NeoplasmsAdultmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaDisease-Free Survival03 medical and health sciencesRegorafenibInternal medicineOverall survivalChemotherapyHumansAgedRetrospective StudiesChemotherapybusiness.industryPhenylurea Compoundsmedicine.diseaseClinical trial030104 developmental biologychemistryQuality of LifePrednisonebusinessOncology
researchProduct

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

2017

Abstract Purpose: There are conflicting results concerning the prognostic value of the CpG island methylator phenotype (CIMP) in patients with nonmetastatic colon cancer. We studied this phenotype in stage III colon cancer characterized for mismatch repair (MMR), RAS, and BRAF status, and treated with adjuvant FOLFOX-based regimen. Experimental Design: Tumor samples of 1,907 patients enrolled in the PETACC-8 adjuvant phase III trial were analyzed. The method used was methylation-specific PCR, where CIMP+ status was defined by methylation of at least 3 of 5 following genes: IGF2, CACNA1G, NEUROG1, SOCS1, and RUNX3. Association between CIMP status and overall survival (OS), disease-free survi…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsAdjuvant chemotherapyColorectal cancermedicine.medical_treatmentLeucovorincolon cancer stage iiiKaplan-Meier EstimateDNA Mismatch Repair[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMethylator phenotypecolorectalCetuximabHematologyMiddle AgedColon cancer stage iiiPrognosisPhenotypeStage III Colon Cancer3. Good healthadjuvant chemotherapyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsoncologyFemaleFluorouracilmedicine.drugmedicine.medical_specialtyphenotype[SDV.CAN]Life Sciences [q-bio]/CancerGastrointestinal tumoursDisease-Free Survivalpatient prognosis03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedNeoplasm StagingChemotherapyCpG Island Methylator Phenotypebusiness.industryProportional hazards modeloxaliplatinCancerDNA Methylationmedicine.diseasedigestive system diseasesOxaliplatin030104 developmental biologyMutationCpG IslandsNeoplasm Recurrence LocalbusinessValue (mathematics)030217 neurology & neurosurgery
researchProduct

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

2017

IF 6.029; International audience; BackgroundThe prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use.Patients and methodsAccording to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study. Primary objective was to compare percentage of patients alive and without recurrence at 2 years in patients with high versus low LI (#NCT02364024). Associations…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentMedizinLeucovorinProspective cohort study[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXOrganoplatinum Compounds/therapeutic useAntineoplastic Combined Chemotherapy ProtocolstudyLymphocytesProspective StudiesProspective cohort studyLeucovorin/therapeutic useMiddle AgedPrognosis3. Good healthColorectal carcinomaOncologyFluorouracil030220 oncology & carcinogenesisPredictive value of testsColonic NeoplasmsBiomarker (medicine)Lymphocytes/pathologyFemaleFluorouracilAdjuvantmedicine.drugAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerFluorouracil/therapeutic useBiomarkers Tumor/analysis03 medical and health sciencesLymphocytes Tumor-InfiltratingPredictive Value of TestsBiomarker; Colorectal carcinoma; Immune response; Prospective cohort study; Oncology; Cancer ResearchInternal medicinemedicineBiomarkers TumorHumansImmune responseSurvival analysisAgedbusiness.industryBiomarkermedicine.diseaseSurvival AnalysisSurgery030104 developmental biologyProspective cohort&nbspMultivariate AnalysisColonic Neoplasms/diagnosisAntineoplastic Combined Chemotherapy Protocols/therapeutic usebusiness
researchProduct

Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure

2018

STUDY QUESTION: Is endometrial recurrent implantation failure (RIF) only a matter of an asynchronous (displaced) window of implantation (WOI), or could it also be a pathological (disrupted) WOI? SUMMARY ANSWER: Our predictive results demonstrate that both displaced and disrupted WOIs exist and can present independently or together in the same RIF patient. WHAT IS KNOWN ALREADY: Since 2002, many gene expression signatures associated with endometrial receptivity and RIF have been described. Endometrial transcriptomics prediction has been applied to the human WOI in two previous studies. One study describes endometrial RIF to be the result of a temporal displacement of the WOI. The other indic…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceprecision medicineBiologyEndometrial tissue03 medical and health sciencesEndometrium0302 clinical medicineImplantation failuretranscriptomic predictorsInternal medicinemedicinepolycyclic compoundsHumansendometrial asynchronyEmbryo Implantationendometrial pathologyendometriumPathologicalRetrospective Studiesrecurrent implantation failure030219 obstetrics & reproductive medicineGene Expression ProfilingRehabilitationConfoundingObstetrics and GynecologyRetrospective cohort studyEmbryo TransferPenetranceGene expression profilinggene expression signatures030104 developmental biologyReproductive Medicinemachine learning predictorswindow of implantation displacementFemaleTranscriptomeInfertility Femaletranscriptomic taxonomy
researchProduct

Impact of ultrasound extraction parameters on the antioxidant properties of Moringa oleifera leaves

2020

Recently, much interest has been focused on Moringa oleifera L., a highly versatile and sustainable plant. In addition to its nutritional properties, numerous bioactive compounds have been identified in M. oleifera leaves, for which healthy properties have been reported. In the present research, the impact of ultrasound-assisted extraction (UAE) on the recovery of the bioactive compounds from leaves was investigated. Firstly, an experimental design approach has been used to highlight the influence of some extraction parameters (solvent, solvent/dry leaves ratio, temperature, time) on phenol compound recovery and antioxidant activity. Solvent composition was the most influential factor

0301 basic medicineOptimizationPhysiologyClinical BiochemistryLiquid chromatographyBiochemistryMoringa03 medical and health scienceschemistry.chemical_compoundMoringa oleifera leaves0404 agricultural biotechnologyFlavonolsDry matterFood scienceGallic acidMolecular Biologychemistry.chemical_classification030109 nutrition & dieteticsLiquid chromatography Moringa oleifera leaves Optimization Phenol compounds UAEExtraction (chemistry)lcsh:RM1-95004 agricultural and veterinary sciencesCell Biology040401 food scienceSolventPhenol compoundslcsh:Therapeutics. PharmacologychemistryUAEKaempferolQuercetin
researchProduct